Log in to post a reply
Feb 19, 2012 05:32PM
Interesting discussion....First, I'd like to add that my most recent bone density scan showed a slight improvement in my lumbar spine and worsening in my hip. If I remember correctly my FRAX score showed an approx 6% risk of fracture in the next 10 years. I also have read about a possible link between bone density loss in post menopausal women and risk of breast cancer recurring to bones. I believe that the latter is an area of insufficient research--someone PLEASE correct me or add knowledge that you may have. Since bone is a primary site for recurrence of breast cancer, I have one more reason for being concerned about bone health.
Ltothe K, I agree that many approaches may contribute to improvement in bone health. You mentioned your boss's improvement, and I wonder whether she has experienced early menopause, breast cancer treatment (chemo, hormonal therapy), or an illness that places her at risk for osteopenia. Trust me, I am just curious. I have dealt with osteopenia for about 15 years, and I have focused on many approaches, including calcium and Vitamin D supplementation, sunlight exposure, weight bearing exercise (yoga, classical stretch, walking, and low weight workouts). I have minimal caffeine intake (dark chocolate--in very small amounts); I do not smoke and I drink about 3-4 glasses of wine a month. Perhaps I would have experienced a greater progression without these approaches, but I also have seen my osteopenia advance over the years (albeit with a slight improvement as noted above). My onc suggested Prolia, and I am still considering it.
Tampa, thanks for your input. SpecialK, thanks for the additional info as well. Please let us know whether your insurance approves or denies. Anyone else have something to contribute?
Brenda.... Wanderer, there is no road, the road is made by walking. (Antonio Machado)
1995, IDC, Left, 1cm, Stage IA, Grade 3, 0/16 nodes, ER+/PR+, HER2-
2006, IDC, Left, 1cm, Stage IA, Grade 3, ER+/PR+, HER2-
2009, IDC, 1cm, Stage IV, Grade 3, mets, ER+/PR+, HER2- (IHC)